Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 4)Google Scholar

Stahl, SM, Buckley, PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr Scand 2007;15:4–11.Google Scholar

Insel, TR. Rethinking schizophrenia. Nature 2010;468:187–93.Google Scholar

McGorry, PD, Yung, AR, Bechdolf, A, Amminger, P. Back to the future: predicting and reshaping the course of psychotic disorder. Arch Gen Psychiatry 2008;65:25–7.CrossRefGoogle Scholar

Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 4)CrossRefGoogle Scholar

Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 4)Google Scholar

Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 5)Google Scholar

Morrisette, DM, Stahl, SM. Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectr 2014;19(5):439–48.Google Scholar

Stahl, SM. Essential psychopharmacology, the prescriber’s guide, seventh edition. New York, NY: Cambridge University Press; 2020.Google Scholar

Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 5)Google Scholar

Roth, BL. Ki determinations, receptor binding profiles, agonist and/or antagonist functional data, HERG data, MDR1 data, etc. as appropriate was generously provided by the National Institute of Mental Health’s Psychoactive Drug Screening Program, Contract # HHSN-271–2008–00025-C (NIMH PDSP). The NIMH PDSP is directed by Bryan L. Roth, MD, PhD at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscol at NIMH, Bethesda, MD, USA. For experimental details please refer to the PDSP website http://pdsp.med.unc.edu.Google Scholar

Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 5)Google Scholar

Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 5)Google Scholar

Stahl, SM. Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr 2016;21:1–6.CrossRefGoogle ScholarPubMed

Stahl, SM. Mechanism of action of cariprazine. CNS Spectr 2016;21:123–7.Google Scholar

Lohr, JB, Eidt, CA, Abdulrazzaq Alfaraj, A, Soliman, MA. The clinical challenges of akathisia. CNS Spectr 2015;20:4–14.CrossRefGoogle ScholarPubMed

Stahl, SM, Loonen, AJ. The mechanism of drug-induced akathisia. CNS Spectr 2011;16(1):7–10.Google Scholar

Fernandez, HH, Factor, SA, Hauser, RA et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology 2017;88(21):2003–10.Google Scholar

Hauser, RA, Factor, SA, Marder, SR et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry 2017;174(5):476–84.Google Scholar

Waln, O, Jankovic, J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y) 2013;3:tre-03-161-4138-1. doi:10.7916/D88P5Z71.Google ScholarPubMed

Stahl, SM. Essential psychopharmacology, the prescriber’s guide, seventh edition. New York, NY: Cambridge University Press; 2020.Google Scholar

Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 5)Google Scholar

Stahl, SM. Essential psychopharmacology, the prescriber’s guide, seventh edition. New York, NY: Cambridge University Press; 2020.Google Scholar

Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 5)Google Scholar

Maroney, M. An update on the current treatment strategies and emerging agents for the management of schizophrenia. Am J Manag Care 2020;26(3 Suppl): S55–61.Google Scholar

Stahl, SM. Case studies: Stahl’s essential psychopharmacology. New York, NY: Cambridge University Press; 2011.CrossRefGoogle Scholar

Stahl, SM. Essential psychopharmacology, the prescriber’s guide, seventh edition. New York, NY: Cambridge University Press; 2017.Google Scholar

Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 5)Google Scholar

Stahl, SM. Essential psychopharmacology, the prescriber’s guide, seventh edition. New York, NY: Cambridge University Press; 2017.Google Scholar

Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 5)Google Scholar

Pandurangi, AK, Dalkilic, A. Polypharmacy with second-generation antipsychotics: a review of evidence. J Psychiatr Pract 2008;14:345.Google Scholar

Royal College of Psychiatrists. CR138. Consensus Statement on High-Dose Antipsychotic Medication. 2006. Available at: www.rcpsych.ac.uk/docs/default-source/members/faculties/rehabilitation-and-social-psychiatry/rehab-cr190.pdf?sfvrsn=d8397218_4.Google Scholar

Stahl, SM. Essential psychopharmacology, the prescriber’s guide, seventh edition. New York, NY: Cambridge University Press; 2020.CrossRefGoogle Scholar

Roth, BL. Ki determinations, receptor binding profiles, agonist and/or antagonist functional data, HERG data, MDR1 data, etc. as appropriate was generously provided by the National Institute of Mental Health’s Psychoactive Drug Screening Program, Contract # HHSN-271–2008–00025-C (NIMH PDSP). The NIMH PDSP is directed by Bryan L. Roth, MD, PhD at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscol at NIMH, Bethesda, MD, USA. For experimental details please refer to the PDSP website http://pdsp.med.unc.edu.Google Scholar

Santana, N, Mengod, G, Artigas, F. Expression of alpha 1-adrenergic receptors in rat prefrontal cortex: cellular co-localization with 5-HT_2A receptors. Int J Neuropsychopharmacol 2013;16(5):1139–51.Google Scholar

Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 5)Google Scholar

Neuroscience Education Institute. Recommended ANC monitoring [pdf]. 2017.Google Scholar

Stahl, SM. Essential psychopharmacology, the prescriber’s guide, seventh edition. New York, NY: Cambridge University Press; 2020.Google Scholar

Stahl, SM. Essential psychopharmacology, the prescriber’s guide, seventh edition. New York, NY: Cambridge University Press; 2017.Google Scholar

Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 5)Google Scholar

Meyer, JM. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed. CNS Spectr 2017;22(Suppl):17–27.Google Scholar

Spanarello, S, La Ferla, T. The pharmacokinetics of long-acting antipsychotic medications. Curr Clin Pharmacol 2014;9(3):310–17.Google Scholar

Stahl, SM. Stahl’s essential psychopharmacology, fifth edition. New York, NY: Cambridge University Press; 2021. (Chapter 5)Google Scholar

Krogmann, A, Peters, L, von Hardenberg, L et al. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectr 2019;24(S1):38–69.Google Scholar

Maroney, M. An update on the current treatment strategies and emerging agents for the management of schizophrenia. Am J Manag Care 2020;26(3 Suppl):S55–61.Google Scholar

Muly, EC, Votaw, JR, Ritchie, J, Howell, LL. Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone. J Pharmacol Exp Ther 2012;341(1):81–9.Google Scholar

Snyder, GL, Vanover, KE, Hongwen, Z et al. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology (Berl) 2015;232(3):605–21.CrossRefGoogle ScholarPubMed

Maroney, M. An update on the current treatment strategies and emerging agents for the management of schizophrenia. Am J Manag Care 2020;26(3 Suppl): S55–61.Google Scholar

Stahl, SM. Essential psychopharmacology, the prescriber’s guide, seventh edition. New York, NY: Cambridge University Press; 2020.CrossRefGoogle Scholar